Carbapenem Utilization, Resistance Patterns, and Clinical Outcomes Among Critically Ill Patients: Insights from Sudan
Sudan Journal of Medical Sciences · 30.06.2026 · 21 (2) · 183-199
DOI: 10.18502/sjms.v21i2.19723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sudan Journal of Medical Sciences, online erschienen am 30.06.2026. Verfasst von Noran N. Mohammed und 7 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Carbapenems are critical antibiotics for the treatment of severe infections in critically ill patients. Inappropriate use promotes resistance, particularly in resource-limited settings such as Sudan. Therefore, this study aimed to assess carbapenem utilization, resistance patterns, and in-ICU (Intensive Care Unit) mortality.
Methods
A retrospective cohort study was conducted in the ICU at Royal Care International Hospital, Khartoum, Sudan, from January to December 2022. The data were collected using a predesigned checklist and analyzed using SPSS v22; categorical variables were compared using the Chi-square test, with P < 0.05 considered significant.
Results
A total of 156 patients were included, most of whom were male (93, 60.0%) and aged >70 years (69, 44.2%). Meropenem was the predominant carbapenem prescribed to 128 (82.0%) patients. Empirical therapy accounted for most prescriptions (141, 90.4%), of which 83% (117/141) were appropriate, while the remaining 17% (24/141) were inappropriate. Positive cultures were obtained from 52 (38.5%) patients, with 24 (20.7%) Pseudomonas spp. and 21 (18.1%) Acinetobacter baumannii as the most common isolates. Resistance was highest in A. baumannii (21/21; 100% resistant to both meropenem and imipenem) and Klebsiella pneumoniae (9/9, 100% to meropenem; 8/9, 88.9% to imipenem), while moderate resistance was observed in Pseudomonas spp. (16/24, 66.7% to meropenem; 13/24, 54.2% to imipenem). Clinical outcomes showed infection control in 56 (35.9%) patients, uncontrolled infection in 27 (17.3%), and death in 69 (44.2%). In an unadjusted analysis, no significant association was found between the type of prescription and clinical outcome (P = 0.33).
Conclusion
Carbapenems were widely prescribed, mostly empirically, with little deescalation and high resistance. Stronger stewardship, timely cultures, and guideline-based use are vital to curb resistance and improve ICU outcomes in resource-limited settings.
Zitieren
APA
Mohammed, N. N., Hamadalneel, Y. B., Alnazeer, M. H., Mustafa, M. A., Elhag, E. A. A., Ahmed, K. O., Babekir, E., & Yousef, B. A. (2026). Carbapenem Utilization, Resistance Patterns, and Clinical Outcomes Among Critically Ill Patients: Insights from Sudan. Sudan Journal of Medical Sciences, 21(2), 183-199. https://doi.org/10.18502/sjms.v21i2.19723
Vancouver
Mohammed NN, Hamadalneel YB, Alnazeer MH, Mustafa MA, Elhag EAA, Ahmed KO, et al. Carbapenem Utilization, Resistance Patterns, and Clinical Outcomes Among Critically Ill Patients: Insights from Sudan. Sudan Journal of Medical Sciences. 2026;21(2):183-199. doi:10.18502/sjms.v21i2.19723
BibTeX
@article{Mohammed2026,
author = {Mohammed, Noran N. and Hamadalneel, Yousif B. and Alnazeer, Mohammed H. and Mustafa, Mawahib A. and Elhag, Elkhanssa Abdelhameed Ahmed and Ahmed, Kannan O. and Babekir, Elmoiz and Yousef, Bashir A.},
title = {Carbapenem Utilization, Resistance Patterns, and Clinical Outcomes Among Critically Ill Patients: Insights from Sudan},
journal = {Sudan Journal of Medical Sciences},
year = {2026},
volume = {21},
number = {2},
pages = {183--199},
doi = {10.18502/sjms.v21i2.19723}
}
EUVIMED